2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T5c40,

Summary Table

Domain	Detail
Risk Factors	Southeast Asian or Southern Chinese descent, Epstein-Barr virus (EBV) infection, consumption of salt-preserved fish (nitrosamines), family history, HLA subtypes (A2, B17, B46), male sex, age 40-60 years
Etiology	Strong association with EBV; dietary nitrosamines and genetic susceptibility act as co-factors
Patient Presentation	Painless unilateral neck mass (cervical lymphadenopathy), nasal obstruction, epistaxis, serous otitis media with unilateral conductive hearing loss, cranial nerve palsies in advanced disease
Classic Physical Exam	Firm, non-tender posterior cervical or upper jugular lymph node; mass in the fossa of Rosenmuller on nasopharyngeal examination; middle ear effusion on otoscopy; cranial nerve deficits (CN III, IV, V, VI if skull base involvement)
Key Diagnostic Results	Nasopharyngeal biopsy showing undifferentiated carcinoma (WHO Type III) with lymphoepithelial pattern; elevated EBV viral capsid antigen (VCA) IgA and EBV DNA titers; CT/MRI showing mass in the nasopharynx with skull base erosion
Management	Concurrent chemoradiation (cisplatin + radiation) is the mainstay; radiation therapy alone for early-stage (T1N0); adjuvant chemotherapy with cisplatin/5-FU for advanced stages
Keywords	"Southeast Asian male," "painless neck mass," "unilateral serous otitis media in an adult," "fossa of Rosenmuller," "EBV-associated," "undifferentiated nasopharyngeal carcinoma"

1. Pathophysiology

Nasopharyngeal carcinoma (NPC) arises from the epithelial lining of the nasopharynx, with a strong predilection for the fossa of Rosenmuller (pharyngeal recess), a small mucosal depression located just posterior and superior to the torus tubarius. This anatomic location is critical because its proximity to several important structures explains the diverse clinical manifestations of this tumor.

EBV plays a central etiologic role, particularly in the endemic (undifferentiated) subtype. The virus infects nasopharyngeal epithelial cells and drives oncogenesis through expression of latent membrane proteins (LMP1, LMP2) and EBV nuclear antigens, which promote cell proliferation, inhibit apoptosis, and facilitate immune evasion. Elevated EBV VCA-IgA and plasma EBV DNA levels serve as both diagnostic and prognostic biomarkers.

The tumor spreads locally by invading the skull base, which gives access to the cavernous sinus and the cranial nerves traversing it. This is why patients may present with cranial nerve palsies involving CN III, IV, V (particularly V2), and VI. Lateral extension toward the parapharyngeal space can compress CN IX through XII. The tumor has a remarkable tendency for early lymphatic dissemination to retropharyngeal and upper cervical lymph nodes, which is why up to 70-80% of patients present with cervical lymphadenopathy as their initial complaint rather than primary site symptoms.

Obstruction of the Eustachian tube orifice by the tumor leads to negative middle ear pressure and subsequent serous otitis media. A unilateral middle ear effusion in an adult, particularly one from an endemic region, should always raise suspicion for NPC until proven otherwise. Posterior nasal obstruction and mucosal ulceration account for the symptoms of nasal blockage and epistaxis.

2. Classification and Clinical Manifestation

WHO Histologic Classification

Type	Name	Description	EBV Association	Geography
Type I	Keratinizing squamous cell carcinoma	Resembles typical SCC with keratin pearls and intercellular bridges	Low	More common in non-endemic areas (Western countries)
Type II	Non-keratinizing differentiated carcinoma	Mature differentiation but without keratinization	Moderate-High	Intermediate
Type III	Non-keratinizing undifferentiated carcinoma	Sheets of undifferentiated cells with prominent lymphocytic infiltrate (lymphoepithelioma)	Very High (nearly 100%)	Dominant in endemic regions (Southeast Asia, Southern China)

WHO Type III is the most common subtype overall and the most commonly tested. Despite being poorly differentiated, it paradoxically carries the best prognosis among all subtypes because it is highly radiosensitive and tends to elicit a robust immune response (reflected by its dense lymphocytic infiltrate).

Clinical Manifestation by Region of Spread

Region of Involvement	Clinical Manifestation
Nasopharynx (primary site)	Epistaxis, nasal obstruction, blood-tinged postnasal drip
Eustachian tube	Unilateral serous otitis media, conductive hearing loss, ear fullness
Cervical lymph nodes	Painless, firm, unilateral posterior cervical or jugulodigastric mass
Skull base / Cavernous sinus	Cranial nerve palsies: diplopia (CN VI most common), facial numbness (CN V), ptosis (CN III)
Parapharyngeal space	Trismus, lower cranial nerve deficits (CN IX-XII), Horner syndrome
Distant metastases	Bone pain, hepatomegaly, pulmonary nodules (bone, liver, lung are common metastatic sites)

The classic clinical triad taught for NPC is: (1) cervical lymphadenopathy, (2) nasal symptoms (epistaxis/obstruction), and (3) unilateral ear complaints (serous otitis media). In practice, the neck mass is often the presenting symptom that brings the patient to medical attention.

3. Diagnostic Workup

Diagnostic Summary Table

Test	Role	Key Finding
Nasal endoscopy with biopsy	Gold standard / Confirmatory test	Direct visualization of nasopharyngeal mass (fossa of Rosenmuller); histopathology confirms WHO type
EBV serology (VCA-IgA, EA-IgA)	Screening / Supportive	Elevated titers support the diagnosis; useful in endemic populations for screening
Plasma EBV DNA	Prognostic and monitoring	Correlates with tumor burden, stage, and treatment response
MRI of nasopharynx and neck	Best imaging modality	Superior soft tissue contrast for assessing primary tumor extent, skull base invasion, retropharyngeal nodes, and intracranial extension
CT of nasopharynx	Complementary imaging	Better for detecting bony erosion of the skull base and clivus
PET-CT	Staging (advanced disease)	Identifies distant metastases; useful for treatment planning and post-treatment surveillance
Audiometry + Tympanometry	Supportive	Documents conductive hearing loss and type B tympanogram from middle ear effusion

Nasal endoscopy with biopsy is the definitive diagnostic step. When a patient from an endemic background presents with a neck mass or unilateral serous otitis media, endoscopic examination of the nasopharynx is mandatory. The fossa of Rosenmuller must be carefully inspected, as early lesions can be subtle. A punch or forceps biopsy provides the tissue for histopathologic confirmation.

EBV serology is highly useful as a screening and adjunctive tool. Elevated VCA-IgA and early antigen (EA)-IgA titers are found in a large proportion of NPC patients, often preceding clinical symptoms. In endemic regions, EBV serology is used for population-level screening. However, serology alone is not confirmatory because elevated titers can be found in other EBV-related conditions.

Plasma EBV DNA quantification has become an increasingly important tool. Pre-treatment levels correlate with tumor stage and volume. A persistently elevated or rising EBV DNA level after treatment is a strong indicator of residual or recurrent disease. It is now widely used for post-treatment surveillance.

MRI is the preferred imaging modality for evaluating the primary tumor. It provides superior delineation of soft tissue extent, perineural spread, intracranial extension, and retropharyngeal lymphadenopathy compared to CT. CT remains complementary when evaluating bony destruction of the skull base. For distant staging, PET-CT is the standard for detecting metastases in bone, liver, and lungs.

One important exam point: in any adult presenting with unilateral serous otitis media without an obvious cause (such as recent upper respiratory infection), the workup must include nasopharyngeal examination to exclude NPC. Performing myringotomy alone without examining the nasopharynx is an incomplete and potentially dangerous approach.

4. Management and Treatment

Management Summary Table

Stage	Treatment	Details
Early stage (T1N0M0)	Radiation therapy alone	Intensity-modulated radiation therapy (IMRT) is the standard; total dose approximately 70 Gy over 7 weeks to the primary site
Locally advanced (T2-T4 and/or node-positive)	Concurrent chemoradiation	Cisplatin 40 mg/m$^2$ weekly or 100 mg/m$^2$ every 3 weeks during radiation
Adjuvant chemotherapy	After concurrent chemoradiation for stage III-IVB	Cisplatin 80 mg/m$^2$ Day 1 + 5-Fluorouracil 1000 mg/m$^2$/day continuous infusion Days 1-4, every 4 weeks for 3 cycles
Induction chemotherapy (alternative)	Before chemoradiation for bulky advanced disease	Gemcitabine + Cisplatin (GP regimen) for 3 cycles, followed by concurrent chemoradiation
Recurrent / Metastatic	Systemic therapy with or without re-irradiation	Gemcitabine/cisplatin as first-line palliative chemotherapy; immunotherapy with anti-PD-1 agents (e.g., pembrolizumab, camrelizumab) for progressive disease
Supportive care	Throughout all stages	Dental evaluation before radiation, speech and swallow rehabilitation, nutritional support, audiologic monitoring

Radiation therapy is the backbone of NPC treatment because the tumor is exceptionally radiosensitive, particularly the undifferentiated (WHO Type III) subtype. IMRT is the current standard technique because it allows precise dose delivery to the irregularly shaped nasopharyngeal target volume while sparing adjacent critical structures such as the parotid glands, temporal lobes, brainstem, and spinal cord. This significantly reduces long-term toxicity, particularly xerostomia (dry mouth from parotid damage), which was a major complication of older radiation techniques.

For early-stage disease (T1N0), radiation therapy alone achieves excellent control rates (over 90% five-year survival), and adding chemotherapy provides no additional benefit while increasing toxicity.

For locally advanced disease, the landmark Intergroup 0099 trial established concurrent cisplatin-based chemoradiation followed by adjuvant cisplatin/5-FU as the standard of care. Cisplatin acts as a radiosensitizer, enhancing the cytotoxic effects of radiation on tumor cells. The concurrent phase typically uses cisplatin at 100 mg/m$^2$ given on Days 1, 22, and 43 of the radiation course. The adjuvant phase follows with three cycles of cisplatin and 5-FU.

More recent evidence supports induction chemotherapy (gemcitabine plus cisplatin) before chemoradiation as an alternative sequencing strategy for locally advanced disease, showing improved failure-free survival in several trials.

Contraindications and adjustments: Cisplatin is nephrotoxic and ototoxic, requiring adequate hydration, monitoring of renal function, and audiometric surveillance. In patients with renal impairment, carboplatin can be substituted. Radiation to the nasopharynx commonly causes xerostomia, mucositis, dysphagia, and hypothyroidism (from incidental thyroid irradiation), all of which require proactive management.

Surgery has a very limited role in primary NPC management due to the deep anatomic location and difficulty achieving clear margins. It is reserved for salvage treatment of localized recurrences that are not amenable to re-irradiation.

5. Differential Diagnosis and Distractors

Differential Diagnosis	Why It Is Similar	Key Discriminator
Lymphoma (e.g., NK/T-cell nasal type)	Can present as a nasopharyngeal mass with cervical lymphadenopathy in a similar demographic; also EBV-associated	Lymphoma typically shows midline nasal destruction (lethal midline granuloma) with necrotic ulceration; biopsy shows lymphoid markers (CD56+, cytoplasmic CD3+) rather than epithelial origin; immunohistochemistry and flow cytometry differentiate
Nasopharyngeal angiofibroma	Presents with nasal obstruction and epistaxis in a young patient; mass visible in the nasopharynx	Occurs almost exclusively in adolescent males; highly vascular tumor that bleeds profusely on biopsy (biopsy is contraindicated if suspected); CT shows a mass in the sphenopalatine foramen with Holman-Miller sign
Adenoid hypertrophy	Causes nasal obstruction and serous otitis media; visible on lateral neck X-ray or endoscopy	Occurs in children, typically bilateral; no cervical mass; tissue is benign lymphoid hyperplasia; resolves with age or adenoidectomy
Cholesteatoma	Can present with conductive hearing loss and ear fullness	Shows retraction pocket or pearly white mass behind the tympanic membrane on otoscopy; no nasopharyngeal mass; destructive temporal bone changes on CT
Parotid tumor	Presents as a painless neck/preauricular mass in an adult	Mass is located in the parotid region (preauricular or angle of mandible), not in the posterior cervical triangle; no nasopharyngeal findings; diagnosed by fine-needle aspiration and MRI
Tuberculous lymphadenitis (scrofula)	Presents as a neck mass, particularly in endemic TB regions	Nodes are often matted with overlying skin changes or sinus tracts; positive tuberculin skin test/interferon-gamma release assay; biopsy shows caseating granulomas; no nasopharyngeal mass
Metastatic SCC from other head and neck primary	Cervical lymphadenopathy with squamous histology	History of tobacco/alcohol use; primary tumor typically arises from the oropharynx, larynx, or oral cavity; different anatomic distribution of lymph node involvement; keratinizing histology; HPV association in oropharyngeal SCC

6. Traps and High-Yield Pearls

The single most common way students miss NPC questions is by failing to connect a unilateral serous otitis media in an adult to a nasopharyngeal malignancy. The vignette will describe a middle-aged Southeast Asian male with persistent ear fullness and conductive hearing loss, and the trap answer will be to perform myringotomy with tube insertion or to treat empirically for otitis media. The correct next step is always to examine the nasopharynx first. Any adult with unexplained unilateral middle ear effusion requires nasopharyngeal evaluation before any other intervention.

A second common trap involves the painless neck mass. The vignette may emphasize the neck mass without initially mentioning nasal or ear symptoms, tempting students toward a diagnosis of lymphoma or a branchial cleft cyst. The discriminator is the demographic (Southeast Asian descent), the posterior cervical/jugulodigastric location, and associated EBV markers. When lymphoma is offered as a distractor, remember that NPC is an epithelial tumor, not a lymphoid one, and histopathology with immunohistochemistry will differentiate the two.

Third, students often confuse NPC with juvenile nasopharyngeal angiofibroma because both involve the nasopharynx. The key distinction is patient age and sex: angiofibroma occurs in adolescent males and is vascular (biopsy is contraindicated), while NPC occurs in middle-aged adults and requires tissue biopsy for diagnosis.

Finally, remember that NPC is the head and neck cancer where radiation is the primary treatment modality, not surgery. This is the opposite of most other head and neck squamous cell carcinomas, where surgery followed by adjuvant radiation is standard. The test-writer is evaluating whether you understand that the deep nasopharyngeal location and high radiosensitivity of NPC make chemoradiation the treatment of choice, and that surgery is reserved only for recurrence salvage.

1e:["$","$L2d",null,{"article":{"id":"44dc55f3-c94a-4edd-8f52-6a009b34142d","title":"Karsinoma Nasofaring","content":"$2e","category":"THT-KL","created_at":"2026-05-15T12:53:36.812285+00:00","status":"published","subcategory":null},"questionCount":5,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]